Another win for CogState
Tuesday, 12 August, 2008
CogState [ASX: CGS] has signed a contract worth $1.2 million which will see the company provide technology to a major pharmaceutical company for use in a Phase III schizophrenia study.
The cognition specialist company will be providing its computerised cognitive testing technology for the trial, which is to be conducted in over 70 sites.
This is the ninth contract the company has signed since July.
The nine contracts have a combined value of $2.3 million, and CogState is expecting that 63 per cent of the contracts' revenue will be earned in the coming financial year.
Genetics shape our personality and life outcomes more than we thought
Scientists have identified more than 1200 genetic variants associated with personality traits,...
High folic acid in pregnancy could cause early bleeding
Women taking at least 800 micrograms of folic acid daily were more likely to report spotting and...
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
